Eckert & Ziegler stock costs EUR 12.36 with target 74.8 percent higher

Published on 10/12/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eckert & Ziegler stock costs EUR 12.36 on October 12, 2026 after EUR 12.36. The analyst target is EUR 21.60, 74.8 percent above the price.

Key points in brief

Eckert & Ziegler stock stood at EUR 12.36 at Lang & Schwarz on October 12, 2026 at 1:25 p.m. CEST.
The price matched the Xetra close of October 9, 2026 and sat 30.29 percent below the 52-week high.
The average 12-month analyst target was EUR 21.60, 74.76 percent above the price, based on three analysts.
The next scheduled third-quarter 2026 earnings release is November 12, 2026.

Flatlay mit Aktienzertifikat ISIN DE0005659700, Isotopenfläschchen und Dosimeter auf Marmor — Eckert & Ziegler DE0005659700 Medizintechnik: Flatlay mit Aktienzertifikat, Isotopenfläschchen, Dosimeter und Elementen-Karten, Illustration mit AI erstellt.

Eckert & Ziegler stock was trading at EUR 12.36 at Lang & Schwarz on October 12, 2026 at 1:25 p.m. CEST, exactly matching the Xetra close of October 9, 2026. Investing.com lists an average 12-month target of EUR 21.60 from three analysts, 74.76 percent above the price.

Price sits below yearly high

The stock's 52-week range was EUR 11.91 to EUR 17.73 as of October 12, 2026. At EUR 12.36, Eckert & Ziegler was 30.29 percent below the high and 3.78 percent above the low, placing the quote near the lower end of its annual range.

The latest structured quote for the Xetra listing gave a market capitalization of EUR 775.3 million, a P/E ratio of 15.68, a dividend yield of 0.02 percent and volume of 34,771 shares at 1:02 p.m. CEST on October 12, 2026. The average volume was 115,747 shares, making the session volume 69.96 percent below that average.

Valuation and sector comparison

For context, the company operates in medical isotopes, radiopharmaceutical applications and related healthcare technology. Its investor materials identify two operating segments, Medical and Isotope Products, and reported 2025 revenue of EUR 312.0 million and adjusted EBIT of EUR 77.7 million.

The next scheduled reporting date is November 12, 2026, when the company is expected to publish its third-quarter 2026 results, according to the Marketscreener calendar. That date gives the valuation figures a defined near-term reference point without changing the current price picture.

Comparison with peers

Eckert & Ziegler: unchanged, P/E 15.68, market capitalization EUR 775.3 million
Siemens Healthineers (Xetra, EUR): plus 0.43 percent, P/E 19.85, market capitalization EUR 44.0 billion
Sartorius (Xetra, EUR): plus 0.51 percent, P/E 89.86, market capitalization EUR 17.6 billion

Next reporting date is November 12

The market profile combines a EUR 12.36 price with a 15.68 P/E ratio and a 30.29 percent gap to the annual high. The scheduled November 12, 2026 report is the next dated company event for investors tracking whether operating performance can support the valuation.

The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.